Amylyx Pharmaceuticals (AMLX) CLO gets 21,284 shares in PSU vesting

Q: How many AMLX shares does Gina Mazzariello hold after this Form 4 transaction?

After the reported award, Chief Legal Officer Gina Mazzariello directly holds 200,374 shares of Amylyx Pharmaceuticals, Inc. common stock, according to the Form 4 filing.

Q: What type of equity did AMLX grant to Gina Mazzariello in this Form 4?

Amylyx Pharmaceuticals, Inc. granted performance share units (PSUs) to Chief Legal Officer Gina Mazzariello. These PSUs represented 21,284 shares of Common Stock, which vested upon the achievement of certain performance metrics on August 18, 2026.

Q: Was the AMLX Form 4 transaction a market purchase or a compensation award?

The Form 4 for Amylyx Pharmaceuticals (AMLX) records a grant/award acquisition, not a market purchase. The 21,284 shares were delivered at a reported price of $0.00 per share as vested performance share units (PSUs).

Q: Did AMLX indicate use of a Rule 10b5-1 trading plan for this Form 4 transaction?

No. The filing indicates the Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false), and there is no footnote stating that the award was made pursuant to a Rule 10b5-1 trading plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Legal Officer Gina Mazzariello acquired additional equity-based compensation. On August 18, 2026, she received 21,284 shares of Common Stock represented by performance share units (PSUs) that were awarded upon the achievement of certain performance metrics and vested on that date. Following this award, she directly holds 200,374 shares of Amylyx Pharmaceuticals common stock.

Insider Trade Summary

Net Buyer: 21,284 shares

Net Buy 1 txn

Insider Mazzariello Gina

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock ^F1	21,284	$0.00	$0.00

Holdings After Transaction: Common Stock — 200,374 shares (Direct)

Footnotes (1)

F1. The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.

Key Figures

Shares acquired: 21,284 shares of Common Stock Price per share: $0.00 per share Shares owned after transaction: 200,374 shares +1 more

4 metrics

Shares acquired 21,284 shares of Common Stock Grant/award acquisition on August 18, 2026 represented by PSUs

Price per share $0.00 per share Reported transaction price for the PSU-related share delivery

Shares owned after transaction 200,374 shares Direct holdings of Gina Mazzariello after the award

Transaction date August 18, 2026 Vesting date of the PSUs and acquisition of shares

Key Terms

performance share units, PSUs, vested

3 terms

PSUs financial

"represented by performance share units, or PSUs, and were awarded"

PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.

vested financial

"Shares subject to the PSU vested on August 18, 2026"

FAQ

What insider transaction did AMLX disclose for Gina Mazzariello?

Amylyx Pharmaceuticals (AMLX) disclosed that Chief Legal Officer Gina Mazzariello received an award of 21,284 shares of Common Stock on August 18, 2026, represented by performance share units (PSUs) that vested upon achievement of specified performance metrics.

How many AMLX shares does Gina Mazzariello hold after this Form 4 transaction?

After the reported award, Chief Legal Officer Gina Mazzariello directly holds 200,374 shares of Amylyx Pharmaceuticals, Inc. common stock, according to the Form 4 filing.

What type of equity did AMLX grant to Gina Mazzariello in this Form 4?

Amylyx Pharmaceuticals, Inc. granted performance share units (PSUs) to Chief Legal Officer Gina Mazzariello. These PSUs represented 21,284 shares of Common Stock, which vested upon the achievement of certain performance metrics on August 18, 2026.

Was the AMLX Form 4 transaction a market purchase or a compensation award?

The Form 4 for Amylyx Pharmaceuticals (AMLX) records a grant/award acquisition, not a market purchase. The 21,284 shares were delivered at a reported price of $0.00 per share as vested performance share units (PSUs).

Did AMLX indicate use of a Rule 10b5-1 trading plan for this Form 4 transaction?

No. The filing indicates the Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false), and there is no footnote stating that the award was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 09:00 PM Accepted by SEC EDGAR 08/20/2026 - 09:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazzariello Gina

(Last)

(First)

(Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/18/2026		A		21,284⁽¹⁾	A	$0	200,374	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.

	/s/ Joshua B. Cohen, as Attorney in Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR